For ConnectiveRx's co-pay assistance programs, should we emphasize broader coverage across more medications or deeper discounts for a select few high-cost treatments?

Introduction

The trade-off we're examining for ConnectiveRx's co-pay assistance programs is whether to emphasize broader coverage across more medications or deeper discounts for a select few high-cost treatments. This decision is crucial for balancing patient access, program sustainability, and overall impact on healthcare affordability. I'll analyze this trade-off by considering key stakeholders, metrics, and potential outcomes to provide a strategic recommendation.

Step 1

Clarifying Questions (3 minutes)

• Based on the current healthcare landscape, I'm thinking affordability is a major concern for patients. Could you provide more context on the types of medications currently covered and their average costs?

Why it matters: Helps understand the scope of the problem and potential impact on patients Expected answer: Mix of common and specialty drugs with varying costs Impact on approach: Would influence the balance between breadth and depth of coverage

• Considering ConnectiveRx's business model, I assume there's a financial constraint on the total amount of assistance provided. Can you share how the program is funded and if there are any specific budget limitations?

Why it matters: Determines the feasibility of expanding coverage or increasing discounts Expected answer: Limited budget from pharmaceutical partnerships or internal funding Impact on approach: Would help prioritize allocation of resources

• Looking at user behavior, I'm curious about the current utilization rates of the co-pay assistance program. Do we have data on how many eligible patients are actually using the program?

Why it matters: Indicates potential for program optimization and user education Expected answer: Moderate utilization with room for improvement Impact on approach: Might suggest focusing on increasing awareness before expanding coverage

• From a technical perspective, I'm wondering about the scalability of our current system. How flexible is our platform in terms of adding new medications or adjusting discount levels?

Why it matters: Determines the feasibility of implementing changes quickly Expected answer: Moderately flexible system with some limitations Impact on approach: Would influence the timeline and complexity of implementing changes

• Considering the competitive landscape, how do our co-pay assistance offerings compare to other similar programs in the market?

Why it matters: Helps position our strategy relative to competitors Expected answer: Mixed positioning, stronger in some areas, weaker in others Impact on approach: Would inform whether to focus on differentiation or parity